"It All Depends": A Qualitative Study of Parents' Views of Human Papillomavirus Vaccine for their Adolescents at Ages 11-12 years

被引:16
|
作者
Hansen, Caitlin E. [1 ]
Credle, Marisol [2 ,3 ]
Shapiro, Eugene D. [1 ,4 ,5 ]
Niccolai, Linda M. [2 ,3 ,4 ]
机构
[1] Yale Univ, Dept Pediat, Sch Med, POB 208064, New Haven, CT 06520 USA
[2] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06520 USA
[3] Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Yale Univ, Grad Sch Arts & Sci, Dept Invest Med, New Haven, CT 06520 USA
基金
美国国家卫生研究院;
关键词
HPV; HPV vaccine; Qualitative; HPV VACCINATION; GIRLS; OPPORTUNITIES; CANCER;
D O I
10.1007/s13187-014-0788-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Routine vaccination with three doses of human papillomavirus (HPV) vaccine is recommended for adolescent girls and boys at 11 or 12 years of age; however, vaccine uptake remains suboptimal. To understand the reasons why parents may accept or refuse HPV vaccine for their children at age 11 or 12 years, we conducted a qualitative study. Semi-structured interviews were conducted with parents or guardians (n = 45) whose adolescents receive care at an urban, hospital-based primary care practice. Data were analyzed using an iterative thematic approach. We found that many parents expressed high levels of support for HPV vaccine, including a majority who agreed with vaccination at age 11-12 years. Parents recognized that for prevention of consequences of HPV infection, vaccination of their child early in adolescence was desirable conceptually. However, many parents also expressed that in practice, HPV vaccine should be given to adolescents at the onset of sexual activity, a perception that led to preferences to delay administration of HPV vaccine among certain parents. These apparently contradictory views indicate the need for interventions focused on the benefits of vaccination at the recommended ages. Our findings may be useful in providers' discussions with parents about the vaccine, as pediatric and adolescent health care providers have the unique opportunity to educate parents and clarify misconceptions about vaccination.
引用
收藏
页码:147 / 152
页数:6
相关论文
共 27 条
  • [21] A qualitative study to assess school nurses' views on vaccinating 12-13 year old school girls against human papillomavirus without parental consent
    Stretch, Rebecca
    McCann, Rosemary
    Roberts, Stephen A.
    Elton, Peter
    Baxter, David
    Brabin, Loretta
    BMC PUBLIC HEALTH, 2009, 9
  • [22] Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial
    Lehtinen, Matti
    Eriksson, Tiina
    Apter, Dan
    Hokkanen, Mari
    Natunen, Kari
    Paavonen, Jorma
    Pukkala, Eero
    Angelo, Maria-Genalin
    Zima, Julia
    David, Marie-Pierre
    Datta, Sanjoy
    Bi, Dan
    Struyf, Frank
    Dubin, Gary
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (12) : 3177 - 3185
  • [23] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
    Einstein, Mark H.
    Baron, Mira
    Levin, Myron J.
    Chatterjee, Archana
    Fox, Bradley
    Scholar, Sofia
    Rosen, Jeffrey
    Chakhtoura, Nahida
    Meric, Dorothee
    Dessy, Francis J.
    Datta, Sanjoy K.
    Descamps, Dominique
    Dubin, Gary
    HUMAN VACCINES, 2011, 7 (12): : 1343 - 1358
  • [24] Exploring the relationship between vaccine hesitancy and mothers' perspectives on COVID-19 vaccines for children ages 5-11 years during the omicron predominant period 2021-2022: a qualitative study
    Suragh, Tiffany A.
    Adzrago, David
    Allicock, Marlyn A.
    Yeh, Paul G.
    Cuccaro, Paula
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [25] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2-and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial
    Leung, Ting Fan
    Liu, Anthony Pak-Yin
    Lim, Fong Seng
    Thollot, Franck
    Oh, Helen May Lin
    Lee, Bee Wah
    Rombo, Lars
    Tan, Ngiap Chuan
    Rouzier, Roman
    Friel, Damien
    De Muynck, Benoit
    De Simoni, Stephanie
    Suryakiran, Pemmaraju
    Hezareh, Marjan
    Folschweiller, Nicolas
    Thomas, Florence
    Struyf, Frank
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (07) : 1689 - 1702
  • [26] Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
    Einstein, Mark H.
    Takacs, Peter
    Chatterjee, Archana
    Sperling, Rhoda S.
    Chakhtoura, Nahida
    Blatter, Mark M.
    Lalezari, Jacob
    David, Marie-Pierre
    Lin, Lan
    Struyf, Frank
    Dubin, Gary
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3435 - 3445
  • [27] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study
    Einstein, Mark H.
    Levin, Myron J.
    Chatterjee, Archana
    Chakhtoura, Nahida
    Takacs, Peter
    Catteau, Gregory
    Dessy, Francis J.
    Moris, Philippe
    Lin, Lan
    Struyf, Frank
    Dubin, Gary
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3455 - 3465